- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05593107
68Ga-N188 PET/CT Imaging in Malignancy
A Study to Evaluate 68Ga-N188 PET/CT Imaging of Nectin-4 Expression in Malignant Tumors
The Nectin-4 protein belongs to the cell adhesion factors family and has a tissue-specific expression spectrum in normal human tissues. However, Nectin-4 is overexpressed in various malignancies, especially those of epithelial origins, such as uroepithelial carcinoma, making Nectin-4 a highly specific and significant imaging target for malignancies.
[68Ga]N188, a novel molecular probe of PET imaging agent that targets Nectin-4, can be used in the diagnosis and research of a wide variety of Nectin-4 high-expression malignancies, including bladder cancer.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jianhua Zhang, Dr.
- Phone Number: +861083572791
- Email: zjhjn820@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100034
- Recruiting
- Peking University First Hospital
-
Contact:
- Jianhua Zhang
- Phone Number: +861083572791
- Email: zjhjn820@163.com
-
Principal Investigator:
- Jianhua Zhang, Dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients with confirmed or suspected cancer;
- 18F-FDG PET/CT within 1 week;
- Signed written informed consent.
Exclusion Criteria:
- Pregnant and lactating women;
- Female patients plan to become pregnant within 6 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: [68Ga]N188
Subjects with suspected or confirmed malignancy will receive an intravenous injection of 68Ga-N188 followed by PET imaging.
The subjects will also receive a whole-body 18F-FDG PET/CT scan within a one-week period.
|
68Ga-N188 is injected intravenously with a dose of 0.06-0.08
mCi/kg.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The diagnostic efficacy of 68Ga-N188 PET/CT in the evaluation of malignant tumors
Time Frame: 1 year
|
Compare the standardized Uptake Value (SUV) of lesions on 68Ga-N188 and 18F-FDG PET/CT
|
1 year
|
The diagnostic efficacy of 68Ga-N188 PET/CT in the evaluation of malignant tumors
Time Frame: 1 year
|
Compare the number of lesions detected by 68Ga-N188 and 18F-FDG PET/CT, based on the pathology or clinical follow-up as gold standard.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The dosimetry of 68Ga-N188
Time Frame: 1 year
|
Research on the dose distribution of 68Ga-N188 in healthy volunteers and cancer patients by 1-hour dynamic PET/CT acquisition and analyze by the dosimetry software
|
1 year
|
Quantitative evaluation of 68Ga-N188
Time Frame: 1 year
|
Evaluation of quantitative parameters of 68Ga-N188, such as time-activity curve.
|
1 year
|
Correlation with pathological expression
Time Frame: 1 year
|
Analyze Nectin-4 expression at the imaging level in combination with Nectin-4 expression in pathological specimens
|
1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- [68Ga]N188
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
John M. BuattiNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedUterine Cervical Neoplasms | Prostatic Neoplasms | Rectal Neoplasms | Endometrial Neoplasms | Anus NeoplasmsUnited States
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
Russian Society of Colorectal SurgeonsRecruitingNeoplasms,ColorectalRussian Federation
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Novartis PharmaceuticalsBayerCompletedColorectal Neoplasms | Rectal Neoplasms | Colonic NeoplasmsUnited States, Germany, Belgium, Canada, Spain, United Kingdom, Taiwan, France, Switzerland, Sweden, Portugal, New Zealand, Italy, Slovakia, Australia, Austria, Brazil, Hong Kong
Clinical Trials on [68Ga]N188
-
Peking Union Medical College HospitalRecruiting
-
Peking Union Medical College HospitalRecruiting
-
PentixaPharm GmbHTerminated
-
Yusuf MendaNational Cancer Institute (NCI); National Institutes of Health (NIH); Holden...Active, not recruiting
-
Peking University Cancer Hospital & InstitutePeking University Health Science CenterRecruiting
-
Xiangya Hospital of Central South UniversityCompleted
-
First Affiliated Hospital of Fujian Medical UniversityCompletedTumor Positron-Emission TomographyChina
-
IpsenTerminated
-
Peking Union Medical College HospitalUnknownLymphatic DisordersChina
-
The First Affiliated Hospital of Xiamen UniversityRecruiting